1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 12,900 | 16,300 | 07:00 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.09. | Adlai Nortye auf der Morgan Stanley Global Healthcare Conference: Fokus auf RAS-Inhibitoren | 1 | Investing.com Deutsch | ||
| 10.09. | Jefferies initiates Adlai Nortye stock with buy rating on drug potential | 3 | Investing.com | ||
| 10.09. | Adlai Nortye: Jefferies sieht dank Medikamentenkandidat massives Kurspotenzial | 1 | Investing.com Deutsch | ||
| ADLAI NORTYE GROUP Aktie jetzt für 0€ handeln | |||||
| 08.09. | Adlai Nortye Group Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 08.09. | Lucid Capital Markets initiates Adlai Nortye stock with buy rating | 2 | Investing.com | ||
| 08.09. | Lucid Capital Markets startet Coverage für Adlai Nortye mit Kaufempfehlung und massivem Kurspotenzial | 2 | Investing.com Deutsch | ||
| 08.09. | Adlai Nortye: Erster Patient in klinischer Studie mit Krebsmedikament AN4035 behandelt | 1 | Investing.com Deutsch | ||
| 26.08. | Adlai Nortye Group Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 14.08. | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 14.08. | Adlai Nortye GAAP EPS of -$0.04, revenue of $13.06M | 2 | Seeking Alpha | ||
| 14.08. | Adlai Nortye Ltd. Reports Unaudited First Half 2026 Financial Results and Highlights Recent Operational Progress | 679 | GlobeNewswire (Europe) | Enrollment ongoing in both QD and QW arms of global Phase I trial of pan-RAS(ON) inhibitor AN9025 First regulatory approval obtained for Phase I trial of pan-RAS(ON) ADC AN4035 Two leading medical... ► Artikel lesen | |
| 03.08. | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 03.08. | Adlai Nortye receives approval to begin trial in Australia | 3 | Investing.com | ||
| 03.08. | Adlai Nortye erhält Zulassung für klinische Studie in Australien | 3 | Investing.com Deutsch | ||
| 03.08. | Adlai Nortye Ltd.: Adlai Nortye Announces Clinical Trial Notification Submission and HREC Approval for the Phase I Clinical Trial of Pan-RAS(ON) Inhibitor ADC AN4035 in Australia | 349 | GlobeNewswire (Europe) | First-in-class pan-RAS(ON) ADC is cleared for clinical development Designed to selectively deliver pan-RAS(ON) inhibition to tumors while minimizing systemic toxicity. IND submissions to U.S. FDA... ► Artikel lesen | |
| 17.07. | Adlai Nortye Ltd. - 6-K, Report of foreign issuer | - | SEC Filings | ||
| 16.07. | Adlai Nortye doses first patient in weekly trial arm of AN9025 | 1 | Investing.com | ||
| 16.07. | Adlai Nortye startet wöchentliche Dosierungsstudie für Krebswirkstoff AN9025 | 1 | Investing.com Deutsch | ||
| 16.07. | Adlai Nortye Ltd.: Adlai Nortye Announces First Patient Dosed in Intermittent Weekly Dosing Arm of Global Phase 1 Trial of Pan-RAS(ON) Inhibitor AN9025 | 289 | GlobeNewswire (Europe) | First patient dosed in intermittent QW dosing arm with AN9025 Intermittent dosing offers a differentiated approach in the pan-RAS(ON) inhibitor space and may widen the therapeutic window based on... ► Artikel lesen | |
| 13.07. | Adlai Nortye expands scientific advisory board with two oncologists | 3 | Investing.com |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CLINUVEL | 5,086 | -0,86 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL date of Annual General Meeting | ||
| BIOCRYST PHARMACEUTICALS | 7,616 | 0,00 % | BioCryst Pharmaceuticals, Inc.: BioCryst Announces Approval of ORLADEYO for Pediatric HAE Patients in Japan | - Expands availability of the first and only oral prophylactic therapy for patients with HAE ages 2 to RESEARCH TRIANGLE PARK, N.C., Aug. 25, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc.... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,658 | +0,73 % | Cardiol Therapeutics Inc: Cardiol receives $7M (U.S.) from warrant exercise | ||
| ARBUTUS BIOPHARMA | 4,360 | -0,46 % | Arbutus Biopharma Corp-Aktie im Check am 17.09. (08:40 Uhr): Meine aktuelle Lageeinschätzung | ||
| CARDIFF ONCOLOGY | 1,206 | +3,34 % | Cardiff Oncology, Inc.: Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement | SAN DIEGO and NERVIANO, Italy, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (NASDAQ: CRDF) ("Cardiff") and Nerviano Medical Sciences S.r.l. ("NMS") today announced that they have reached... ► Artikel lesen | |
| ALDEYRA | 1,210 | -0,82 % | Aldeyra Therapeutics, Inc. - 10-Q, Quarterly Report | ||
| DENALI THERAPEUTICS | 19,110 | +1,24 % | Mehr als 98% bleiben draußen: Warum Roche, Denali und NurExone neue Wege ins Nervensystem suchen | ||
| ABCELLERA BIOLOGICS | 11,080 | +0,18 % | AbCellera-Aktie mit +18% - neues Allzeithoch möglich? | Die AbCellera-Aktie hat zuletzt erneut einen kräftigen Kurssprung hingelegt. Am gestrigen Handelstag ging es um +17,81% nach oben. Damit setzt sich die außergewöhnliche Rallye fort: Seit dem lokalen... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 23,320 | -4,86 % | Adaptive Biotechnologies Announces Update to NCCN Guidelines for Multiple Myeloma, Strengthening MRD Testing Recommendations and Specifically Referencing clonoSEQ | Updated guidelines establish a dedicated framework for routine MRD assessment across the multiple myeloma patient journey clonoSEQ named as an FDA-cleared assay for MRD assessment, with 10-6 sensitivity... ► Artikel lesen | |
| AC IMMUNE | 2,415 | +1,05 % | AC Immune SA: AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 | AC Immune Announces Positive Preliminary Phase 1 Data for NLRP3 Inhibitor ACI-19764 ACI-19764 is an orally available inhibitor of the NLRP3 inflammasome Preliminary data showed ACI-19764 was safe... ► Artikel lesen | |
| COHERUS ONCOLOGY | 1,173 | +3,71 % | Coherus auf Morgan Stanley Konferenz: Onkologie-Strategie gewinnt an Dynamik | ||
| CYTOMX THERAPEUTICS | 2,626 | +2,42 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ("Varseta-M") for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) | - Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in... ► Artikel lesen | |
| CYBIN | 12,340 | +2,83 % | Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change | TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) ("Helus" or the "Company"), a clinical-stage pharmaceutical company committed to helping minds heal by developing... ► Artikel lesen | |
| AGENUS | 7,600 | 0,00 % | Agenus Inc.: Agenus Announces Three BOT+BAL Presentations Spanning Neoadjuvant and Late-Line Colorectal Cancer and Advanced Sarcomas at ESMO 2026 | Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three abstracts from investigator-sponsored trials evaluating botensilimab and balstilimab (BOT+BAL) have... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 14,400 | 0,00 % | Arcturus to present Phase 2 data for OTC deficiency treatment |
ADLAI NORTYE GROUP LTD ADR gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -1,000 (-6,67 %) liegt der Kurs bei 14,000 Euro. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ADLAI NORTYE GROUP LTD ADR finden Sie auf Wallstreet Online.